308 results on '"Fajac, I."'
Search Results
2. P045 Lenticlair™ 1: A phase 1/2 trial evaluating the safety, tolerability and efficacy of an inhaled F/HN-pseudotyped lentiviral vector for CF gene therapy in people with CF ineligible for CFTR modulators
3. WS06.03 Efficacy and safety of elexacaftor/tezacaftor/ivacaftor (ELX/TEZ/IVA) in people with cystic fibrosis and ELX/TEZ/IVA-responsive, non-F508del genotypes: a phase 3, randomised, placebo-controlled trial
4. WS11.04 Evaluation of lung computed tomography screening of patients with cystic fibrosis according to a modified Lung-RADS score
5. P046 Lenticlair™-ON: An extension trial examining long-term safety and efficacy outcomes associated with an inhaled F/HN-pseudotyped lentiviral vector for CF gene therapy in people with cystic fibrosis
6. P481 MRI as a follow-up to lung CT to evaluate suspicious lung nodules using a modified Lung-RADS scoring system in patients with cystic fibrosis
7. Building global development strategies for cf therapeutics during a transitional cftr modulator era
8. Cystic fibrosis drug trial design in the era of CFTR modulators associated with substantial clinical benefit: stakeholders’ consensus view
9. Genomically-guided therapies: A new era for cystic fibrosis
10. Cibler les canaux ioniques : une voie thérapeutique pour la mucoviscidose
11. Preface
12. 185 Long-term safety and efficacy of elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis heterozygous for F508del-CFTR and a gating or residual function mutation
13. Mucoviscidose : nouvelles thérapeutiques ciblant la protéine CFTR
14. WS21.01 AQP5 and CFTR, two genes associated with pseudo-aquagenic palmoplantar keratoderma?
15. New clinical diagnostic procedures for cystic fibrosis in Europe
16. Guideline on the design and conduct of cystic fibrosis clinical trials: The European Cystic Fibrosis Society–Clinical Trials Network (ECFS-CTN)
17. Amikacin liposome inhalation suspension for chronic Pseudomonas aeruginosa infection in cystic fibrosis
18. Mucoviscidose : du bon usage des explorations fonctionnelles respiratoires
19. Explorations fonctionnelles respiratoires du grand enfant ou de l’adulte atteint de mucoviscidose: Respiratory function tests for older children and adults with cystic fibrosis
20. S66 Impact of elexacaftor/tezacaftor/ivacaftor triple combination therapy on health-related quality of life in people with cystic fibrosis homozygous for F508del (F/F): results from a Phase 3 clinical study
21. S65 Impact of elexacaftor/tezacaftor/ivacaftor triple combination therapy on health-related quality of life in people with cystic fibrosis heterozygous for F508del and a minimal function mutation (F/MF): results from a Phase 3 clinical study
22. Glycofection: facilitated gene transfer by cationic glycopolymers
23. Intracellular rate-limiting steps of gene transfer using glycosylated polylysines in cystic fibrosis airway epithelial cells
24. Channelopathies in bronchiectasis
25. CFTR DYSFUNCTION INDUCES VEGF SYNTHESIS IN AIRWAY EPITHELIUM IN VITRO AND IN VIVO IN MICE: 165
26. WS11.5 Evaluation of combinations of the CFTR potentiator dirocaftor, corrector posenacaftor and amplifier nesolicaftor in cystic fibrosis subjects with two copies of the F508del mutation
27. P222 An update on BALANCE-CF™ 1: a Phase II trial of the inhaled ENaC inhibitor BI 1265162 in adults and adolescents with cystic fibrosis
28. ePS3.10 Patient demographics and baseline disease characteristics in a multicentre, randomised, double-blind, placebo-controlled phase 2b study of lenabasum, a selective cannabinoid receptor type 2 agonist, in cystic fibrosis
29. P221 Impact of elexacaftor/tezacaftor/ivacaftor triple combination therapy on health-related quality of life in people with cystic fibrosis heterozygous for F508del and a minimal function mutation: results from a Phase 3 clinical study
30. WS19.6 Impact of elexacaftor/tezacaftor/ivacaftor (ELX/TEZ/IVA) triple combination therapy on health-related quality of life (HRQoL) in people with cystic fibrosis (pwCF) homozygous for F508del (F/F): results from a Phase 3 clinical study
31. Non-classic cystic fibrosis associated with D1152H CFTR mutation
32. Reduced exhaled NO is related to impaired nasal potential difference in patients with cystic fibrosis
33. LATE-ONSET CYSTIC FIBROSIS AND PROLONGED SURVIVAL IN SUBJECTS WITH D1152H CFTR MUTATION: 225
34. INTRACELLULAR TRAFFICKING OF PLASMID/LACTOSYLATED POLYETHYLENIMINE COMPLEXES AFTER NASAL INSTILLATION IN MICE: 273
35. CYTOSKELETAL INVOLVEMENT IN THE CELLULAR TRAFFICKING OF PLASMID/PEI DERIVATIVE COMPLEXES: 274
36. Recombinant Escherichia coli as a gene delivery vector into airway epithelial cells
37. Targeting of cell receptors and gene transfer efficiency: a balancing act
38. Nasal airway ion transport is linked to the cystic fibrosis phenotype in adult patients
39. Mutations located in exon 24 of the CFTR gene are associated with a mild cystic fibrosis phenotype
40. P066 Disease progression and burden in patients with cystic fibrosis homozygous for F508del across Europe in an observational registry (VOICE Study)
41. WS06-1 Initial results evaluating combinations of the novel CFTR corrector PTI-801, potentiator PTI-808, and amplifier PTI-428 in cystic fibrosis subjects
42. Étude observationnelle chez des patients atteints de mucoviscidose traités par ivacaftor en France : efficacité clinique lors de la première analyse intermédiaire de l’étude BRIO
43. Étude observationnelle chez des patients atteints de mucoviscidose et traités par ivacaftor en France : première analyse intermédiaire de l’utilisation des ressources en santé dans l’étude BRIO
44. SAFETY, TOLERABILITY AND EARLY SIGNS OF EFFICACY WITH RIOCIGUAT FOR THE TREATMENT OF ADULT PHE508DEL HOMOZYGOUS CYSTIC FIBROSIS PATIENTS: STUDY DESIGN AND RATIONALE FOR THE RIO-CF STUDY
45. PND80 - AN OBSERVATIONAL STUDY OF IVACAFTOR IN PATIENTS WITH CYSTIC FIBROSIS IN FRANCE: FIRST INTERIM ANALYSIS OF HEALTH CARE RESOURCE UTILIZATION FROM THE BRIO STUDY
46. P028 Riociguat for the treatment of adult Phe508del homozygous cystic fibrosis: efficacy data from the Phase II Rio-CF study
47. WS01.2 Phase 2 initial results evaluating PTI-428, a novel CFTR amplifier, in patients with cystic fibrosis
48. EPS1.3 Safety, tolerability and early signs of efficacy with riociguat for the treatment of adult Phe508del homozygous cystic fibrosis patients: study design and rationale for the Rio-CF study
49. Croissance démographique et thérapeutiques ciblées : le nouveau visage de la mucoviscidose
50. 112 Analysis of long-term use of liposomal amikacin for inhalation (LAI) in patients with cystic fibrosis (CF) who have chronic infection from Pseudomonas aeruginosa
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.